Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    XTL Biopharmaceuticals Ltd ADR logo
    XTLB

    XTL Biopharmaceuticals Ltd ADR

    MaveScore 17 Low model confidence
    Last Price US$2.30 As of Jun 15, 2026
    Market Cap US$2.0b Company size context
    7D Performance 3.14% Past 7 days
    1Y Performance 109.09% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2025

    167 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    11/16

    5 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 17 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    11/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    2/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    15/15 Strong

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    XTL Biopharmaceuticals Ltd ADR Overview

    Industry: Biotechnology

    Sector: Healthcare

    XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

    XTL Biopharmaceuticals Ltd ADR is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review XTL Biopharmaceuticals Ltd ADR in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    Will XTLB stock attract ESG investors - 2025 Macro Impact & Weekly Momentum Stock Picks
    2 hours ago
    News Image
    Will XTLB stock attract ESG investors - CEO Change & Momentum Based Trading Signals
    5 hours ago
    News Image
    Can XTLB stock hit analyst price targets - July 2025 Pullbacks & Long-Term Growth Plans
    12 hours ago

    XTL Biopharmaceuticals Ltd ADR Competitors

    XTL Biopharmaceuticals Ltd ADR operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    XTL Biopharmaceuticals Ltd ADR

    US$2.30

    US$2.0b

    3.14%

    109.09%